Stock ESALY EISAI CO., LTD.
Add to a list
To use this feature you must be a member
Log inSign up
Inactive Instrument

All News Eisai Co., Ltd. OTC Markets

Equities

ESALY

US2825793092

All News

Search
See the results
Unlock all the news: Be the first to know and act before the market!
100% Free Registration
FDA approves a second Alzheimer's drug that can modestly slow disease
AQ
Eli Lilly Alzheimer's drug approved by US FDA
RE
Eisai Announces Move to Solo Development and Commercialization of Farletuzumab Ecteribulin (FZEC) Antibody Drug Conjugate (ADC)
AQ
Eisai Repurchases 4.8 Billion Yen Worth of Shares in June
MT
Tranche Update on Eisai Co., Ltd.'s Equity Buyback Plan announced on May 15, 2024.
CI
Japan's Eisai developing dementia drug for US market, Nikkei reports
RE
EISAI - NEW EFFICACY DATA FOR NON-CLEAR CELL RENAL CELL CARCINOMA FROM KEYNOTE-B61 ADDED TO LENVIMA US LABEL SUPPORTING KEYTRUDA + LENVIMA INDICATION FOR THE FIRST-LINE TREATMENT OF ADULT PATIENTS WITH ADVANCED RCC
AQ
Eisai: "LEQEMBI" (Lecanemab) for the Treatment of Alzheimer's Disease Launched in China
AQ
Eisai and Biogen launch Alzheimer's drug Leqembi in China
RE
Eisai Co., Ltd. and Biogen Inc. Announces Launch of Leqembi in China
CI
Leqembi[®] (lecanemab) launched in China
AQ
Periotherapia Co., Ltd. announced that it has received ¥390 million in funding from Mitsubishi UFJ Capital Co., Ltd., Eisai Co., Ltd., Techno Science, Inc., Chishima Real Estate Co., Ltd., Osaka University Venture Capital Co., Ltd.
CI
Eisai Continues Contract for FY2024 Dementia Examination Project by Tokyo Bunkyo City
AQ
Eisai : Notification Regarding Revision of “Eisai Global Code of Conduct for Business Partners”
PU
Biogen executive plays down looming competition for its Alzheimer's drug
RE
BioArctic AB - FDA accepts filing of Leqembi sBLA for IV maintenance dosing for the treatment of early Alzheimer's disease
AQ
Japan's Nikkei gains on chip shares boost; Fed policy in focus
RE
Japan's Nikkei rises on US stocks, heavyweight chip shares
RE
FDA advisory panel votes in favor of data for Lilly Alzheimer's drug
RE
FDA Accepts Eisai's Filing of LEQEMBI (lecanemab-irmb) Supplemental Biologics License Application for IV Maintenance Dosing for the Treatment of Early Alzheimer's Disease
AQ
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. 4523 Stock
  4. ESALY Stock
  5. News Eisai Co., Ltd.